Today (March 4) another meeting of the Transparency Council.
The agenda includes:
- Preparation of a position paper on the evaluation of the drug Ngenla (somatrogonum) within the framework of the drug program B.19. "Treatment of low-grade children with somatotropin hypopituitarism (ICD-10: E23)".
- Preparation of a position paper on the evaluation of the drug Produodopa (foslevodopum + foscarbidopum) under the drug program B.90. "Treatment of ...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
